Requires conspicuous labeling for any product that has potential to act as gene therapy or that could introduce genetic material to product's users

State: MO
Bill Number: HB 1169
Position: SUPPORT
Action Required: NONE
Status: Died, failed to pass House Emerging Issues Committee, session ended 5/30/2023

Legislation Details:

UPDATE: 5/30/2023 - HB 1169 died. It failed to pass the House Emerging Issues Committee before the session ended on 5/30/2023.

UPDATE: 4/19/2023 - HB 1169 failed to pass the House Emerging Issues Committee on 4/19/2023.

UPDATE: 4/14/2023 - HB 1169 is scheduled for an Executive Session in the House Emerging Issues Committee on Wednesday, 4/19/2023 at 4:30 PM or upon adjournment (whichever is later) in House Hearing Room 6. The agenda is here. The agenda link also has a Live Feed link to view the hearing. There was a committee substitution, but it has not been posted as of 4/15/2023.

UPDATE: 3/22/2023 - HB 1169 was heard in the House Emerging Issues Committee on 3/22/2023 at 4:30 pm. The committee has not voted, so contacting the members and your own legislators to SUPPORT this bill is recommended. The committee members and their contact information is below. 

HB 1169 was introduced 2/15/2023. It is sponsored by Representative Holly Jones

The bill requires conspicuous labeling for any product that has the potential to act as gene therapy or that could introduce genetic material in to the user of the product. It requires the producer to provide information upon request. There is no restriction on mRNA technology in the bill.

The bill's summary is posted online

This bill specifies that any product that acts as, or exposed to processes that could result in the product potentially acting as, a gene therapy or that could possibly impact, alter, or introduce genetic material or a genetic change into the user of the product or certain other people must be conspicuously labeled with the words "Potential Gene Therapy Product", and reasonable steps must be taken to ensure a potential purchaser or user is made aware of the presence of this label. If a product is known to be a gene therapy product, the product must be conspicuously labeled with the words "Gene Therapy Product".
Upon the written request, any entity that produces, sells, or distributes a product with the capacity to infect an individual with a disease or to expose an individual to certain genetically modified material must provide all information related to the ways in which individuals who did not directly obtain or use such product may be exposed to the product or a component of the product. Any product manufacturer, government agency, or organization that has an interest in the production, sale, or distribution of such a product is also subject to the disclosure requirement and must provide all relevant reports, research, and knowledge upon request. Information requested must be provided as soon as reasonably practicable, but at least within 21 days, after receipt of the written request.
Any entity that makes a product available that could infect, transmit to, or be absorbed in any way that would act as a medical intervention, vaccine, drug, or genetic modification must obtain fully informed consent from all individuals who could be exposed to such product before exposure may occur. Fully informed consent requires, at a minimum, that an individual is made aware of all benefits and risks, including side effects, of the product, any adverse events of special interest, and any other reasonably possible impacts of the product.

NVIC issued a statement recommending mRNA vaccines be withdrawn from the market: While HB 1169 does not directly address human mRNA vaccines, it would provide consumers the information on the mRNA status of the meat, vegetables, and processed food they purchase, so true informed consent could be exercised. mRNA technology is planned for consumer products as discussed in these articles:

House Emerging Issues Committee

Representative Bill Hardwick,Chair, 573-751-3834
Representative Dane Diehl, 573-751-4065
Representative Ashley Aune, 573-751-3618
Representative Bishop Davidson, 573-751-2381
Representative Jeff Farnan, 573-751-9465
Representative Sherri Gallick, 573-751-1344
Representative Mike Haffner, 573-751-3783
Representative Dave Hinman, 573-751-2176
Representative Josh Hurlbert, 573-751-0246
Representative Jamie Johnson, 573-751-9760
Representative Holly Jones, 573-751-7535
Representative Doug Mann, 573-751-2134
Representative Adam Schnelting, 573-751-5365
Representative David Tyson Smith, 573-751-9753

Email Addresses:
[email protected], [email protected], [email protected], [email protected], [email protected], [email protected], [email protected], [email protected], [email protected], [email protected], [email protected], [email protected], [email protected], [email protected] - text, status, and history of HB 1169